Loading company…
Fujisawa-based biotech developing therapies for cardiovascular, metabolic and renal lifestyle-related diseases.
Scohia Pharma, Inc., doing business as SCOHIA, was founded in 2017 in Fujisawa, Japan. It develops treatments for lifestyle-related diseases, led by SCO-240, an SSTR5 antagonist for growth hormone-related disorders. Masanori Watanabe is CEO. In May 2026 it raised JPY 3 billion in venture funding led by Beyond Next Ventures, with several other investors. Stage: Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in